How long adults with psoriasis and fatty liver disease stay on secukinumab
Looks back at secukinumab use in adults with plaque psoriasis and fatty liver disease.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Badalona, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Valencia, and Zaragoza, SpainSee the 7 sites
- Trial code
- Registry title
- A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 8 Jul 2026
- Expected to end
- 15 Jan 2027
- Type of study
- Observational
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at adults with plaque psoriasis (with or without psoriatic arthritis) and fatty liver disease (MASLD) who started secukinumab between 2021 and 2023 in Spain.
- Age
- 18 to 100 years
- Sex
- All sexes
- Disease stage
- Confirmed plaque psoriasis, with or without psoriatic arthritis, and a confirmed MASLD diagnosis. At least one heart or metabolic risk factor.
- Earlier treatment
- First secukinumab prescription recorded between 01 January 2021 and 31 December 2023. No earlier secukinumab. Secukinumab is their first, second or third biologic medicine.
- Biomarker or test result
- Baseline lab test results must be available.
Main reasons for not taking part
- Signs that MASLD is absent
- Liver cancer or other malignant liver disease
- History of liver transplant
- Alcohol use disorder
- Other chronic liver diseases or decompensated cirrhosis
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patients with a first recorded secukinumab prescription between 01 January 2021 and 31 December 2023
- Patients aged ≥18 years at index date
- Patients with no prior secukinumab exposure in available EMR history
- Secukinumab must be patient's first-, second-, or third-line biologic therapy for psoriasis/psoriatic arthritis (PsA)
- Patients with documented administration per Summary of Product Characteristics dosing recommendations (SmPC)
- Patients with confirmed plaque psoriasis with or without PsA
- Patients with at least one cardiometabolic risk factor
- Patients with a confirmed MASLD diagnosis
- Patients with baseline laboratory data available
Who cannot take part
- Patients with malignant liver disease
- Patients with a history of liver transplantation
- Patients with alcohol use disorder
- Patients with other chronic liver diseases
- Patients with diseases or treatments which cause thrombocytopenia
- Patients with evidence of MASLD absence
- Patients with decompensated cirrhosis; Other protocol-defined inclusion/exclusion criteria may apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in Spain
- Badalona, BarcelonaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- BarcelonaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- MadridHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- MálagaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- San Cristóbal de La Laguna, Santa Cruz De TenerifeHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- ValenciaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- ZaragozaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
About the trial
What the trial wants to find out
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis [PsA]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.
The group in the trial
- Secukinumab Cohort
Adult patients with plaque psoriasis (with or without PsA) and MASLD initiating secukinumab in routine clinical practice in Spain.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- SEC-HOPE: A Multicenter Retrospective Cohort Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
- Plain-language title
- How long adults with psoriasis and fatty liver disease stay on secukinumabGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07683065, who can take part
- Record updated
- 9 November 2026